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Abstract
The immune system is a complex and diverse system in the human body and HIV virus disrupts and destroys it through extremely
complicated but surprisingly logical process. The purpose of this paper is to make an attempt to present a method for the computer-
aided management of HIV infection process by means of a mathematical model describing the dynamics of the host pathogen
interaction with HIV-1. Treatments for the AIDS disease must be changed to more efﬁcient ones in accordance with the disease
progression and the status of the immune system. The level of progression and the status are represented by parameters which are
governed by our mathematical model. It is then exhibited that our model is numerically stable and uniquely solvable. With this
knowledge, our mathematical model for HIV disease progression is formulated and physiological interpretations are provided. The
results of our numerical simulations are visualized, and it is seen that our results agree with medical aspects from the point of view
of antiretroviral therapy. It is then expected that our approach will take to address practical clinical issues and will be applied to the
computer-aided management of antiretroviral therapies.
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1. Antiretroviral therapy for HIV infection
Ongoing HIV replication leads to the damage of immune system and progression of AIDS disease, and a goal
of therapy is the maximal suppression of viral replication. Combination antiretroviral therapy is the foundation of
management of patients with HIV infection. The antiretroviral drugs used in combination regimens need to be used
according to optimal schedules of therapies and dosages.Any decision on antiretroviral therapy need to have a long-term
impact on future options for the patient. At present, many of the most important questions related to the treatment of
HIV disease do not have deﬁnite answers. Among them are the questions of when therapy should be started, what the
best initial regimen is, when a given regimen should be changed, and what it should be changed to when a change is
made. In an effort to facilitate this decision process, the United States Department of Health and Human Services has
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published a series of frequently updated guidelines including the “Principles of Therapy of HIV Infection”, “Guidelines
for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescent”, and “Guidelines for the Prevention of
Opportunistic Infections in Persons Infected with HIV”.
Currently licensed drugs for the treatment of HIV infection fall into two main categories as those that inhibit the
viral reverse transcriptase enzyme and those that inhibit the viral protease enzyme. There are numerous drug–drug
interactions that need to be taken into consideration when using these agents. There are drugs among FDA-approved
reverse transcriptase inhibitors which include the nucleoside and the nonnucleoside analogues should not be used as
monotherapy for HIV infection. Physicians ensure that the patient is also on additional antiretroviral medication. The
reverse transcriptase inhibitors block the HIV replication cycle at the point of RNA-dependent DNA synthesis in the
reverse transcription step. While the nonnucleoside reverse transcriptase inhibitors are quite selective for the HIV-1
reverse transcriptase, the nucleoside analogues inhibit a variety of DNA polymerization reaction in addition to these of
the HIV-1 reverse transcriptase. See also [1]. For this reason, serious side effects are more common with the nucleoside
analogues and include mitochondrial damage that can lead to hepatic steatosis and lactic acidosis as well as peripheral
neuropathy and pancreatitis.
The introduction of the HIV-1 protease inhibitors to the therapy is important. When used as part of initial regimens
in combination with reverse transcriptase inhibitors, these agents have been shown to be capable of suppressing levels
of HIV replication to under 50 copies per milliliter in the majority of patients for a minimum of 3 years. As in the case
of reverse transcriptase inhibitors, resistance to protease inhibitors can develop rapidly in the setting of monotherapy,
and thus these agents should be used as part of combination regimens of therapy. Treatment decisions are based on
the fact that one is dealing with a chronic infection. While early therapy is generally the rule in infectious disease,
immediate treatment of every HIV infected individual when diagnosis are made may not give the best results, and
decisions in therapy takes the balance between risks and beneﬁts into account.At present, a reasonable course of action
is to initiate antiretroviral therapy in anyone with the acute HIV syndrome; patients with symptomatic disease; patients
with asymptomatic disease with CD4+T cell counts < 500 per milliliter or with > 20, 000 copies of HIV/RNA per
milliliter. Once the decision has been made to initiate therapy, the health care providers decide which drugs to use as
the ﬁrst regimen. The decision regarding choice of drugs not only will affect the immediate response to therapy but also
will have implications regarding options for future therapy regimens. The initial regimen is usually the most effective
as the virus has not developed signiﬁcant resistance. See [1] for details.
The two options for initial therapy which are most commonly used today are two different three-drug regimens. The
ﬁrst regimen utilizes two nucleoside analogues and a protease inhibitor. The second regimen utilizes two nucleoside
analogues and a nonnucleoside reverse transcriptase inhibitor. There are no clear data at present on which to base
distinctions between these two approaches. Following the initiation of therapy, a one-log reduction in plasmaHIV/RNA
levels within 1–2 months and eventually a decline in plasma HIV/RNA levels to < 50 copies per milliliter should be
expected. During the same time, there should be a rise in the CD4+T cell counts of 100–150 per milliliter. Other
reasons for a change in therapy include a persistently declining CD4+T cell count, clinical deterioration, or drug
toxicity.
As in the case of initiating therapy, changing therapy may have a lasting impact on future options of therapy. When
changing therapy because of clinical progression or worsening laboratory parameters, it is recommended to attempt to
provide a regimen with at least two new drugs. In the patient in whom a change is made for reasons of drug toxicity,
a replacement of one drug is suggested. Plasma HIV RNA levels and CD4+T lymphocyte counts are to be monitored
every 3–4 months during therapy and more frequently if one is considering a change in regimen or immediately
following a change in regimen. HIV resistance proﬁles should improve outcomes of therapy in patients failing their
current antiretroviral regimen. Rates of disease progression differ among individuals, and treatment decisions are to be
individualized based on plasma HIV levels and CD4+T cell counts. See [3].
In view of these aspects, we have performed numerical simulations for monitoring the HIV disease progression and
change in time of HIV virus population dynamics. In accordance with the visualized numerical results, it is expected
that computer-aided management of antiretroviral therapies may be realized.
2. An HIV infection model
In view of the discussions in Section 1, we may formulate the following mathematical model for describing the
HIV disease progression. Let m denote nonnegative integers m = 0, 1, 2, . . . and represent the mth stages of applied
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therapies. In order to formulate a mathematical model which describes HIV infection dynamics under the mth therapy,
we employ the following parameters:
Symbols T , TI,sm, TI,rm, TIR,sm and TIR,rm denote population of healthy CD4+T cells, that of T cells infected with
virus which are all sensitive to the mth therapy, T cells infected with virus which are partly or totally resistant to the
mth therapy, T cells infected with drug-sensitive virus only but in the resting phase under the mth therapy, and T cells
infected with drug-resistant virus but in the resting phase under the mth therapy. Moreover, Vsm and Vrm stand for the
population of drug-sensitive virus and that of drug-resistant virus under the mth therapy, respectively. In particular, Vs0
evoluted at the initial time t = 0 stands for the original virus which ﬁrst invaded into the human body. Also, Vrm are
generated from Vsm through mutation with mutation rate m under the mth therapy, although Vrm may be changed to a
part of Vsm+1 under the (m + 1)th therapy.
In the case that themth therapy is judged to become ineffective for suppressing the disease progression and extensive
mutation of virus at some time t = tm+1, the therapy is changed to a new therapy called the (m + 1)th therapy which
is supposed to be more effective against the disease. In this case it is crucial to formulate suitable initial conditions at
time t = tm+1 for the (m+ 1)th therapy. For this purpose we suppose that two (drug sensitivity) rates m and m can be
speciﬁed in the following way: sensitive virus under the mth therapy remain to be sensitive under the (m+1)th therapy
with the rate of m. Also, resistant virus under the mth therapy remain to be resistant under the (m + 1)th therapy with
the rate of m. Hence, the initial conditions at time t = tm+1 take the following forms:
Vsm+1(tm+1) = (1 − m)Vrm(tm+1) + mVsm(tm+1),
Vrm+1(tm+1) = mVrm(tm+1) + (1 − m)Vsm(tm+1).
(1) The population dynamics of healthy CD4+T cells may be described by the following equation:
(/t)T = dT ∇2T − vf · ∇T + S + p1,m(Vtotal,m) − T
− [1msmVsm + rmVrm ]T − [1msm + rm ]T − [R,sm + R,rm ]T .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and transportation along the (blood
or lymph) ﬂow ﬁeld vf . The second three terms mean natural supply, supply due to immune response depending upon
the total population
Vtotal,m = Vsm + Vrm ,
and natural mortality, respectively. Also, the third two terms stand for infection of T with drug-sensitive and resistant
virus with infection rates 1msm and rm , respectively. Further, the fourth two terms express infection of T with drug-
sensitive and resistant virus generated from TIR,sm and TIR,rm with infection rates ¯sm and ¯rm , respectively. Finally,
the ﬁfth two terms represent transition from infected T cells to infected T cells, TIR,sm and TIR,rm , in the resting phase
with transition rates R,sm and R,rm , respectively. The transition rates R,sm and R,rm should be measured, although
it should be mentioned that these rates are linked with the population of TIR,sm and TIR,rm in the following way: it is
reasonable to assume that the transition rates R,sm and R,rm are products of pure transition rates R,sm and R,rm and
infection rates in such a way that
R,sm = R,smsm and R,rm = R,rmrm .
We employ the saturation functions
pk,m(	) = p∗k,m	/(ck,m + 	) for 	0 and k = 1, . . . , 4,
p5,m(	) = p∗5,m	/(c5,m + 	) for 	
, =0 for 	<
,
and the treatment function
1m(x, t) = exp(−d1(x)t), t0, x ∈ ,
which is a rapidly decaying positive function on [0,∞] for each x ∈ .
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(2) Secondly, the population dynamics of drug-sensitive virus may be described through the equation:
(/t)Vsm = dVs∇2Vsm − vf · ∇Vsm + (1 − m)p3,m(Vtotal,m)Vsm
+ 1msmVsm + 2mp4,m(Vtotal,m)Vsm − m(t)Vsm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld vf
generated by the circulation system. The second term means that drug-sensitiveness is remained under the mth therapy.
Also, the third two terms stand for the restriction (by 1m and 2m) of regeneration of drug-sensitive virus. Finally, the
last term represents the decay effect due to the immune system under the mth therapy.
Here the function m(t) represents the immune response induced by the immune system. In the normal state, the
count of CD4+T lymphocytes is about 1000 per 1ml. In six weeks after the primary infection, it goes down up to
500 per milliliter. Then the immune system is activated and the amount recovers to 800 per 1ml, although it decreases
about 50–100 counts per 1ml every year and CD4+T cell count turns out to decline below the threshold 250 per 1ml.
This process takes place on the primary stage of infection. Under antiretroviral therapy, the immune system is again
activated to recover the population of CD4+T cells. Therefore the function m(t) may be illustrated as a function of
the form:
Also, we have employed the two treatment functions of the forms:
1m(x, t) = exp(−d1m(x)t), 2m(x, t) = max{exp(−d2m(x)t), d3m(x)},
where d1m, d2m and d3m are bounded positive measurable functions.
(3) Thirdly, the population dynamics of drug-resistant virus may be described by the equation below:
(/t)Vrm = dVr ∇2Vrm − vf · ∇Vrm + p3,m(Vtotal,m)[mVsm + Vrm ] + rmVrm − m(t)Vrm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld vf
generated by the (blood and lymph) circulation system. The second two terms mean generation of drug-resistant virus
and regeneration of drug-resistant virus due to mutation, respectively. Finally, the third two terms stand for regeneration
of drug-resistant virus and immune response of the immune system under the mth therapy.
Here the function m(t) is supposed to be same as in Item (2). Since all the virus involved in this equation are
drug-resistant under the mth therapy, treatment functions of the forms 1m and 2m as introduced in Item (2) are not
included in this equation. It is understood that the above equation may be linked with TI,sm in the sense that
Vsm = Kamp, sm · TI,sm, Vrm = Kamp, rm · TI,rm ,
where Kamp,sm and Kamp,rm mean the ampliﬁcation rates of Vsm and Vrm in CD4+T cells, respectively. It is known
that if an HIV virus individual Vsm or Vrm invade into a CD4+T cell, then over 500 HIV copies are generated.
(4) Fourthly, the following equation may be employed as a governing equation to describe the population dynamics
of drug-sensitive infected cells:
(/t)TI,sm = dTI,S∇2TI,sm − vf · ∇TI,sm − p2,m(Vtotal,m)TI,sm − mTI,sm
+ 1msmVsmT + 1msmT − R,smTI,sm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld
vf . The second two terms mean immune response and natural mortality under the mth therapy, respectively. Also,
the third two terms stand for restriction (by 1m) of drug-sensitive infection and infection with drug sensitive virus
generated fromTIR,sm , respectively. Finally, the last term represents transition fromTI,sm to latently infected cellsTIR,sm .
A. Ida et al. / Journal of Computational and Applied Mathematics 204 (2007) 159–165 163
Here 1m is the treatment function as introduced in Item (2) and the equation is coupledwith TIR,sm through the infection
rate rm :
sm = sm · Kamp, sm · act,sm · TIR,sm
for some sm ∈ [0, 1], an ampliﬁcation rate Kamp,sm and an activation rate act,sm .(5) Fifthly, the population dynamics of drug-resistant infected cells may be described by the following equation:
(/t)TI,rm = dTI,r ∇2TI,rm − vf · ∇TI,rm − p2,m(Vtotal,m)TI,rm − ˆmTI,rm + rmVrmT + rmT − R,rmTI,rm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld
vf . The second two terms mean immune response depending upon the total population Vtotal,m =Vsm +Vrm and natural
mortality, respectively.Also, the third two terms stand for resistant infection and infection with resistant virus generated
from TIR,rm , respectively. Finally, the last term represents transition from TI,rm to latently infected cells TIR,rm . This
equation is coupled with TIR,rm through the infection rate:
rm = rm · Kamp, rm · act,rm · TIR,rm
for some weight rm ∈ [0, 1], an ampliﬁcation rate Kamp, rm and an activation rate act,rm .(6) The population dynamics of drug-sensitive latently infected cells may be described by the following equation:
(/t)TIR,sm = dTIR,s∇2TIR,sm − vf · ∇TIR,sm + R,smTI,sm − ¯mTIR,sm
− 1mact,mTIR,sm − p2,m(Vtotal,m)act,smTIR,sm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection of TIR,sm along the
ﬂow ﬁeld vf . The second two terms mean transition from TI,sm to TIR,sm and natural mortality, respectively. Also, the
ﬁfth term stands for activation of latently infected cells and treatment. Finally, the last term represents immune response
to the activated TIR,sm . The rate R,sm is the transition rate on the mth stage of antiretroviral therapy and ¯m means the
mortality rate which is understood to be small since TIR,sm tend to stay at speciﬁc parts of the lymphatic system for a
comparatively long period such as several months or even a few years.
(7) The following equationmay be employed as a governing equation for the population dynamics of latently infected
drug-resistant cells:
(/t)TIR,rm = dTIR,r ∇2TIR,rm − vf · ∇TIR,rm + R,rmTI,rm − ¯mTIR,rm − p2,m(Vtotal,m)act,rmTIR,rm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld
vf . The second two terms mean transition from TI,rm to TIR,rm and natural mortality, respectively. Finally, the last term
stands for immune response to the activated TIR,rm .
In the mathematical model as mentioned above, we have employed the following rates and coefﬁcients: the rates
sm and rm denote the rates of infection of T cells with virus which are sensitive and resistant to the mth therapy,
respectively. R,sm and R,rm mean the rates of transition from infected T cells with drug-sensitive and drug-resistant
virus to the infected cells in the resting phase under the mth therapy. The rates act,sm and act,rm represent the rates of
activation of TIR,sm and TIR,rm which are transitional to TI,sm and TI,rm , respectively. Kamp,sm and Kamp,rm denote
the rates of ampliﬁcation of Vsm and Vrm generated in TI,sm and TI,rm , respectively. sm , sm , rm and rm mean the
natural mortality rates of TI,sm , TIR,sm , TI,rm and TIR,rm , respectively. Finally, m stands for the mutation rate under
the mth therapy.
Stable solvability of the above mathematical model is veriﬁed by applying the so-called semi-implicit product
formula. The numerical solvability is also treated via the same approach. See [2,4] for detailed veriﬁcations.
3. Numerical simulations
The primary purpose of the numerical simulation is to analyze change in time of the levels of virus and states of
disease progression, the rates of viral turnover, the relationship between immune system activation and viral replication,
and the time at which drug resistance start appearing by mutation. The CD4+T cell count is understood to be the best
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Fig. 1. Simulation results.
indicator of the state of immunologic competence of the patient with HIV infection. Our mathematical model of HIV
infection process encompasses a spectrum ranging from an acute syndrome associated with primary infection to a
prolonged asymptomatic state to advanced disease. An attempt has been made to simulate the following four stages of
theHIV infection processes: the early and later stages of HIV infection, themost crucial stage after the ﬁrst antiretroviral
therapy has started, the second stage after the ﬁrst therapy was changed to a new therapy, and states in the case that
treatment stops. These results of our numerical simulations agree withmedical and physiological aspects.More detailed
and other important physiological aspects will be taken into account in the subsequent studies. See [2].
We depict our simulation results in Fig. 1 which consists of seven graphs. In each graph, the lower curve represents
the change in time of the L1-norm of (nonnegative) parameter and illustrates the infection process in the primary stage,
the change in time of disease progression under the second therapy and the last state after all the therapies have been
stopped. The upper curve in each graph shows the change in time of the L∞-norm of (nonnegative) parameter. These
L∞-curves may also be useful for investigating the stability of numerical computation.
The ﬁrst part from step 0 to step 640 illustrates a period of the primary stage to the stage after infection has been
established. It is observed that treatment-sensitive cells are much more proliﬁc than resistant cells. Treatment-resistant
cells are still not as proliﬁc as sensitive cells. This eventually evolves into a stable state. As mentioned previously, it
is expected that mutation of sensitive virus occurs in the next stage after the establishment of chronic infection. The
second part of the graph from step 640 to step 1280 depicts the change in time of disease progression which takes
A. Ida et al. / Journal of Computational and Applied Mathematics 204 (2007) 159–165 165
place after the ﬁrst antiretroviral therapy has been started.A stable state is quickly reached for each case. The treatment
seems to be effective in the sense that it results in the almost complete destruction of sensitive virus, but this allows the
resistant virus to ﬂourish without strong competition with the immune system. The third part of the graph between step
1280–step 1980 illustrates the change in time of disease progression after the ﬁrst therapy was changed to the second
therapy. At step 1280 we necessitate imposing a new initial condition as mentioned in the ﬁrst part of Section 2. It is
seen from the numerical results that a change in time of disease progression similar to the second stage is repeated.
The last part between step 1280–step 2300 suggests a state after all the treatments have been stopped. This result is
obtained bymeans of the samemodel with no treatments.When treatment stops, resistant virus are present and sensitive
virus increase rapidly. Thus it is likely to reach a state in which both types of cells coexist, and this may cause further
treatment by some more effective therapy to be less effective. These results of our numerical simulations agree with
medical and physiological aspects.
It is best to regard HIV disease as beginning at the time of primary infection and progressing through various
stages.Active virus replication and progressive immunological impairment occur throughout the course of HIV disease
progression in most patients. It should be our next plan to develop a new extended model such that these aspects can
be taken into account, and it is anticipated that our approach could take to address practical clinical issues and applied
to the computer-aided management of antiretroviral therapies.
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